Overview
Patients undergoing elective C-section will be randomized into two groups. The first group will receive one dose of Betamethasone at least 24 hours before scheduled C-section. The second group will receive placebo.
Description
This is a prospective double blinded randomized clinical trial. Patients will be randomized into two groups. Group A will receive one dose of Betamethasone at least 24 hours before scheduled C-section. Group B will receive placebo. The maternal and neonatal outcomes will be studied in order to assess the effect of Betamethasone on respiratory morbidity of the newborn infant.
Eligibility
Inclusion Criteria:
- women with singleton or multiple gestation,
- between 37 and 40 weeks of pregnancy (as calculated from the first day of the last menstrual period)
Exclusion Criteria:
- any medical problem that could affect fetal well-being;
- evidence of intrauterine infection,
- oligohydramnios,
- fetal congenital malformations,
- preeclampsia,
- maternal hypertension,
- severe fetal rhesus sensitization,
- antepartum hemorrhage,
- Intrauterine growth restriction
- preterm rupture of membranes
- preterm delivery
- previously received antenatal steroids less than one month ago
- those who decline to participate in the study.